Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A, B, C, D, E: Vonoprazan 10 mg | Experimental | Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to:
There will be a washout interval of a minimum of 5 days between study drug dosing in each period. |
|
| Sequence B, D, E, C, A: Vonoprazan 10 mg | Experimental | Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to:
There will be a washout interval of a minimum of 5 days between study drug dosing in each period. |
|
| Sequence C, E, B, A, D: Vonoprazan 10 mg | Experimental | Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to:
There will be a washout interval of a minimum of 5 days between study drug dosing in each period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vonoprazan ODT-1 or ODT-2 without Water | Drug | Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Observed Drug Concentration (Cmax) of Vonoprazan | Cmax of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | AUC0-t of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | AUC0-inf of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | Tmax of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Phathom Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 7551 Metro Center Dr Ste 200 | Austin | Texas | 78744 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
A total of 25 healthy participants were enrolled in this 5-period crossover study and were randomized to 1 of 5 treatment sequences to receive vonoprazan as two formulations (orally dispersible tablet [ODT]-1 and ODT-2) with or without water. The reference formulation was vonoprazan 10 milligram (mg) tablets (Treatment E).
This study was conducted at single center in the United States from 14 February 2025 to 10 April 2025.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Vonoprazan 10 mg: Treatment Sequence 1 | Participants received Vonoprazan 10 mg, orally, in the following sequence: ODT-1, once on Day 1 of Period 1 without water as Treatment A, ODT-1, once on Day 1 of Period 2 mixed with water and administered via a syringe as Treatment B, ODT-2, once on Day 1 of Period 3 without water as Treatment C, ODT-2, once on Day 1 of Period 4 mixed with water and administered via a syringe as Treatment D, and Vonoprazan 10 mg tablet, once on Day 1 of Period 5 as Treatment E. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between doses in each treatment period. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 10, 2024 | Dec 3, 2025 |
Not provided
The treatment periods will include administration of single doses of vonoprazan 10 mg on Day 1 of each period. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Not provided
Not provided
Not provided
Not provided
|
| Sequence D, C, A, E, B: Vonoprazan 10 mg | Experimental | Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to:
There will be a washout interval of a minimum of 5 days between study drug dosing in each period. |
|
| Sequence E, A, D, B, C: Vonoprazan 10 mg | Experimental | Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to:
There will be a washout interval of a minimum of 5 days between study drug dosing in each period. |
|
| Vonoprazan ODT-1 or ODT-2 with Water | Drug | Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe |
|
| Vonoprazan (Reference) | Drug | Vonoprazan will be administered orally as a tablet |
|
Tlag of Vonoprazan was reported. |
| Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Terminal Elimination Rate Constant (λz) of Vonoprazan | λz of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Terminal Phase Half-life (t1/2) of Vonoprazan | t1/2 of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Apparent Oral Clearance (CL/F) of Vonoprazan | CL/F of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| Apparent Volume of Distribution (Vz/F) of Vonoprazan | Vz/F of Vonoprazan was reported. | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| FG001 | Vonoprazan 10 mg: Treatment Sequence 2 | Participants received Vonoprazan 10 mg, orally, in the following sequence: ODT-1, once on Day 1 of Period 1 mixed with water and administered via a syringe as Treatment B, ODT-2, once on Day 1 of Period 2 mixed with water and administered via a syringe as Treatment D, Vonoprazan 10 mg tablet, once on Day 1 of Period 3 as Treatment E, ODT-2, once on Day 1 of Period 4 without water as Treatment C, ODT-1, and once on Day 1 of Period 5 without water as Treatment A. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between doses in each treatment period. |
| FG002 | Vonoprazan 10 mg: Treatment Sequence 3 | Participants received Vonoprazan 10 mg, orally, in the following sequence: ODT-2, once on Day 1 of Period 1 without water as Treatment C, Vonoprazan 10 mg tablet, once on Day 1 of Period 2 as Treatment E, ODT-1, once on Day 1 of Period 3 mixed with water and administered via a syringe as Treatment B, ODT-1, once on Day 1 of Period 4 without water as Treatment A and ODT-2, once on Day 1 of Period 5 mixed with water and administered via a syringe as Treatment D. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between doses in each treatment period. |
| FG003 | Vonoprazan 10 mg: Treatment Sequence 4 | Participants received Vonoprazan 10 mg, orally, in the following sequence: ODT-2, once on Day 1 of Period 1 mixed with water and administered via a syringe as Treatment D, ODT-2, once on Day 1 of Period 2 without water as Treatment C, ODT-1, once on Day 1 of Period 3 without water as Treatment A, Vonoprazan 10 mg tablet, once on Day 1 of Period 4 as Treatment E and ODT-1, once on Day 1 of Period 5 mixed with water and administered via a syringe as Treatment B. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between doses in each treatment period. |
| FG004 | Vonoprazan 10 mg: Treatment Sequence 5 | Participants received Vonoprazan 10 mg, orally, in the following sequence: Vonoprazan 10 mg tablet, once on Day 1 of Period 1 as Treatment E, ODT-1, once on Day 1 of Period 2 without water as Treatment A, ODT-2, once on Day 1 of Period 3 mixed with water and administered via a syringe as Treatment D, ODT-1, once on Day 1 of Period 4 mixed with water and administered via a syringe as Treatment B and ODT-2, once on Day 1 of Period 5 without water as Treatment C. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between doses in each treatment period. |
| COMPLETED |
|
| NOT COMPLETED |
|
The safety population included all participants who receive at least 1 dose of study drug. As planned, baseline data was collected and reported as single arm for all 25 participants.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | All participants who were randomized to receive Vonoprazan 10 mg, orally, in one of the five treatment sequence: ODT-1, once on Day 1 of Period 1 without water as Treatment A, ODT-1, once on Day 1 of Period 2 mixed with water and administered via a syringe as Treatment B, ODT-2, once on Day 1 of Period 3 without water as Treatment C, ODT-2, once on Day 1 of Period 4 mixed with water and administered via a syringe as Treatment D, and Vonoprazan 10 mg tablet, once on Day 1 of Period 5 as Treatment E. Each treatment period was 3 days, with treatment received on Day 1 of each treatment period. A washout interval of minimum of 5 days was maintained between each treatment period. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Maximum Observed Drug Concentration (Cmax) of Vonoprazan | Cmax of Vonoprazan was reported. | The Pharmacokinetic (PK) population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Geometric Mean | Geometric Coefficient of Variation | nanogram per milliliter (ng/mL) | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan | AUC0-t of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hour/mL | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan | AUC0-inf of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Geometric Mean | Geometric Coefficient of Variation | ng*hour/mL | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan | Tmax of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Median | Full Range | hours | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan | Tlag of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Median | Full Range | hours | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Terminal Elimination Rate Constant (λz) of Vonoprazan | λz of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Mean | Standard Deviation | per hour | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Terminal Phase Half-life (t1/2) of Vonoprazan | t1/2 of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Mean | Standard Deviation | hours | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Apparent Oral Clearance (CL/F) of Vonoprazan | CL/F of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Mean | Standard Deviation | litres/hour (L/h) | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Apparent Volume of Distribution (Vz/F) of Vonoprazan | Vz/F of Vonoprazan was reported. | The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter. | Posted | Mean | Standard Deviation | litres (L) | Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose |
|
Day 1 to Day 28
All-cause mortality, serious and non-serious adverse events were measured in the safety population, which included all participants who received at least 1 dose of study drug. Safety data are presented for each treatment received, as pre-specified.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Treatment A: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg ODT-1 tablets, orally, once on Day 1 of the allocated period without water. | 0 | 25 | 0 | 25 | 2 | 25 |
| EG001 | Treatment B: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg ODT-1 tablets, orally, once on Day 1 of the allocated period mixed with water and administered via a syringe. | 0 | 25 | 0 | 25 | 0 | 25 |
| EG002 | Treatment C: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg ODT-2 tablets, orally, once on Day 1 of the allocated period without water. | 0 | 25 | 0 | 25 | 1 | 25 |
| EG003 | Treatment D: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. | 0 | 25 | 0 | 25 | 1 | 25 |
| EG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. | 0 | 25 | 0 | 25 | 1 | 25 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Constipation | Gastrointestinal disorders | MedDRA version 27.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA version 27.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA version 27.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA version 27.0 | Systematic Assessment |
| |
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA version 27.0 | Systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA version 27.0 | Systematic Assessment |
|
Principal investigators (PIs) are not permitted to publish the data. Data may be considered for reporting at a scientific meeting or for publication in a scientific journal. In these cases, the sponsor will be responsible for these activities and will work with the PIs to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and any other related issues. The sponsor has final approval authority over all such issues.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Phathom Medical Information | Phathom Pharmaceuticals, Inc. | 1-888-775-7428 | medicalinformation@phathompharma.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Mar 12, 2025 | Dec 3, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D014867 | Water |
| C552956 | 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine |
| ID | Term |
|---|---|
| D006878 | Hydroxides |
| D000468 | Alkalies |
| D007287 | Inorganic Chemicals |
| D000838 | Anions |
| D007477 | Ions |
| D004573 | Electrolytes |
| D010087 | Oxides |
| D017601 | Oxygen Compounds |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Ratio of GLSM (%) | 107.65 | 2-Sided | 90 | 99.67 | 116.28 | GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters. | Equivalence | The two treatments were deemed equivalent if the 90% CIs for the GMRs for all of the parameters were each within 80.00% and 125.00%. |
| Ratio of GLSM (%) | 101.19 | 2-Sided | 90 | 93.68 | 109.30 | GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters. | Equivalence | The two treatments were deemed equivalent if the 90% CIs for the GMRs for all of the parameters were each within 80.00% and 125.00%. |
| Ratio of GLSM (%) | 105.94 | 2-Sided | 90 | 98.08 | 114.43 | GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters. | Equivalence | The two treatments were deemed equivalent if the 90% CIs for the GMRs for all of the parameters were each within 80.00% and 125.00%. |
| Ratio of GLSM (%) | 95.05 | 2-Sided | 90 | 88.00 | 102.67 | GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters. | Equivalence | The two treatments were deemed equivalent if the 90% CIs for the GMRs for all of the parameters were each within 80.00% and 125.00%. |
| Ratio of GLSM (%) | 104.69 | 2-Sided | 90 | 96.93 | 113.08 | GLSM ratios were calculated by taking the antilog of the difference of least square means and associated 90% CIs from the linear mixed effect model analyzing the natural logarithms of the corresponding PK parameters. | Equivalence | The two treatments were deemed equivalent if the 90% CIs for the GMRs for all of the parameters were each within 80.00% and 125.00%. |
| Treatment D: Vonoprazan 10 mg |
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|
Participants received Vonoprazan 10 mg ODT-2 tablets, once on Day 1 of the allocated period mixed with water and administered via a syringe. |
| OG004 | Treatment E: Vonoprazan 10 mg | Participants received Vonoprazan 10 mg tablets, orally, once on Day 1 of the allocated period. |
|
|